Belgium· BE-AMP-SAM664108-00

Azilect 1 mg

A rasagiline product containing rasagiline mesylate, registered in Belgium by Exim Pharma. The same ATC class is registered in 19 of our 19 countries.

ATC N04BD02

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedAzilect 1 mgATCN04BD02REGISTER NO.BE-AMP-SAM664108-00PACKS LISTED2CHECKEDSeptember 26, 2026

Where it is registered

Rasagiline is registered in 19 of 19 countries.

Countries holding a registration under ATC N04BD02 (rasagiline), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 11 of them publish a price we can compare per daily dose

Rasagiline · ATC N04BD02

19 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Italyprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of rasagiline costs, country by country.

Normalised to the WHO defined daily dose (1 mg), the median price runs from $1.28 in France to $3.47 in Spain — a ×2.7 gap.

  • 4 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Rasagiline · price per daily dose (1 mg)

USD · FX 28 Sept 2026

  • ES Spain$3.47
  • CH Switzerland$3.02
  • IT Italy$2.36
  • FR France$1.28
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Rasagiline Mesylate
Manufacturer
Exim Pharma
Country
Belgium (BE)
ATC code
N04BD02
ATC class
Rasagiline
Defined daily dose
1 mg, O
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 2

1 priced
  • be_apb
    4949871
    EUR 129.36
  • be_apb
    7747223

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

200 interactions on record for rasagiline.

Graded by severity as the source publishes them — 28 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Rasagiline · interactions on record

200 records

  • 28 severe
  • 157 moderate

Most severe, free to view

  • FenfluramineA08AA02severe
  • DexfenfluramineA08AA04severe
  • SibutramineA08AA10severe
  • TiclopidineB01AC05severe

15 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Rasagiline in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All rasagiline products

Authorised across Europe · EMA

The same active substance is authorised in 30 EEA countries. Names it is sold under:

  • Austria · Rasagilin +pharma, Rasagilin 1a Pharma
  • Bulgaria · Ралаго, Сагилия
  • Cyprus · Azipron, Rasagiline Krka
  • Czechia · Detreman, Ralago
  • Germany · Rasagea, Rasagilin 1 A Pharma
  • Denmark · Rasagilin Accord, Rasagilin Glenmark
  • Estonia · Ralago, Sagilia
  • Spain · Altina, Neuromiol
  • Finland · Rasabon, Rasagilin
  • France · Rasagiline Accord, Rasagiline Arrow
  • United Kingdom (Northern Ireland) · Azilect, Rasagiline
  • Greece · Asarkin, Ractilen
  • Croatia · Azipron, Ralago
  • Hungary · Ralago, Rasagiline Stada
  • Ireland · Rasagiline Accord, Rasagiline Clonmel
  • Iceland · Azilect, Rasagilin Krka
  • Italy · Aidex, Nalisar
  • Liechtenstein · Azilect, Rasagiline Ratiopharm
  • Lithuania · Ralago, Rasagiline Sandoz
  • Luxembourg · Rasagilin Micro Labs, Rasagiline Eg
  • Latvia · Ralago
  • Malta · Rasagiline Ascend, Sagilia
  • Netherlands · Rasagiline Aurobindo, Rasagiline Bioorganics
  • Norway · Azilect, Rasagilin Accord
  • Poland · Asanix, Detreman
  • Portugal · Detreman, Rasagilina Alras Alter
  • Romania · Hiperavia, Sagilia
  • Sweden · Rasagilin Glenmark, Rasagilin Krka
  • Slovenia · Ralago, Razagilin Krka
  • Slovakia · Ralago, Rasagiline Egis

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/027703bf-2464-4cb0-8525-5fa47c405a33
GET /v1/drugs/027703bf-2464-4cb0-8525-5fa47c405a33?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tablet",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Azilect  1 mg",
  "name_fr": "Azilect  1 mg",
  "name_nl": "Azilect  1 mg",
  "amp_code": "SAM664108-00",
  "strengths": [
    "1.0000",
    "1.0000"
  ],
  "pack_count": 6,
  "substances": [
    "Rasagiline Mesylate",
    "Rasagiline",
    "Mannitol"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Rasagiline",
  "authorisation_numbers": [
    "2098PI0044F003"
  ]
}

See everything about rasagiline.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.